Versipelostatin: Unfolding an unsweetened death

Journal of the National Cancer Institute

Volumn 96, Issue 17, 2004, Pages 1266-1267

  Sausville, Edward A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; BORTEZOMIB; CHAPERONE; CISPLATIN; CYTOTOXIC AGENT; DNA; DNA DEPENDENT PROTEIN KINASE; FLUORODEOXYGLUCOSE F 18; GLUCOSE REGULATED PROTEIN; GLYCOPROTEIN; MEMBRANE PROTEIN; PROTEASOME; PROTEIN BCL 2; PROTEIN IRE1; PROTEIN KINASE; PROTEIN P53; TRANSCRIPTION FACTOR; TUNICAMYCIN; UNCLASSIFIED DRUG; VERSIPELOSTATIN; GLUCOSE; MACROLIDE; OLIGOSACCHARIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EDITORIAL; ENDOPLASMIC RETICULUM; GLYCOLYSIS; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; STOMACH CANCER; TUMOR CELL; ANIMAL; CELL CULTURE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; NOTE; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA DAMAGE; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HUMANS; MACROLIDES; NEOPLASMS; OLIGOSACCHARIDES; TUMOR CELLS, CULTURED;

EID: 4444345412     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh276     Document Type: Editorial

References (10)

1. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti J, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31.
2. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-808.
3. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66.
4. Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. Oncogene 2003;22:7070-7.
5. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002;110:1389-98.
6. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003;100:9946-51.
7. Park HR, Furihata K, Hayakawa Y, Shin-ya K. Versipelostatin, a novel GRP78/Bip molecular chaperone down-regulator of microbial origin. Tetrahedron Lett 2002;43:6941-5.
8. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, et al. Blockade of survival response to glucose deprivation for selective killing of tumor cells. J Natl Cancer Inst 2004;96:1300-30.
9. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8(4 Suppl):S62-7.
10. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology Radiology 2004;231:305-32.